92 related articles for article (PubMed ID: 16488352)
1. An unadjusted NNT was a moderately good predictor of health benefit.
Chong CA; Tomlinson G; Chodirker L; Figdor N; Uster M; Naglie G; Krahn MD
J Clin Epidemiol; 2006 Mar; 59(3):224-33. PubMed ID: 16488352
[TBL] [Abstract][Full Text] [Related]
2. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
Gupta OP; Brown GC; Brown MM
Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
[TBL] [Abstract][Full Text] [Related]
3. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
Roe RH; Lass JH; Brown GC; Brown MM
Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
5. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
[TBL] [Abstract][Full Text] [Related]
6. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
[TBL] [Abstract][Full Text] [Related]
7. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
8. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
10. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
11. [The cost per year of life gained: trends and internal contradictions].
Smulders YM; Thijs A
Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
[TBL] [Abstract][Full Text] [Related]
12. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics.
Farahani P; Levine M; Goeree R
J Eval Clin Pract; 2006 Aug; 12(4):463-70. PubMed ID: 16907691
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II.
Noyes K; Corona E; Zwanziger J; Hall WJ; Zhao H; Wang H; Moss AJ; Dick AW;
Med Care; 2007 May; 45(5):377-85. PubMed ID: 17446823
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
Borg S; Glenngård AH; Osterborg A; Persson U
Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
[TBL] [Abstract][Full Text] [Related]
15. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
16. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
18. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
[TBL] [Abstract][Full Text] [Related]
19. QALYs: is the value of treatment proportional to the size of the health gain?
Nord E; Enge AU; Gundersen V
Health Econ; 2010 May; 19(5):596-607. PubMed ID: 19459186
[TBL] [Abstract][Full Text] [Related]
20. The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error.
Marschner IC; Emberson J; Irwig L; Walter SD
J Clin Epidemiol; 2004 Dec; 57(12):1244-52. PubMed ID: 15617950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
